Alberta Investment Management Corp holds a $6.95 million stake in Encompass Health Co. (NYSE:EHC)

Alberta Investment Management Corp reduced its stake in Encompass Health Co. (NYSE:EHC – Free Report) by 17.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 104,159 shares of the company's stock after selling 22,046 shares during the same period. Alberta Investment Management Corp owned about 0.10% of Encompass Health worth $6,949,000, according to its most recent SEC filing.

Other institutional investors have also recently increased or reduced their stakes in the company. TFO Wealth Partners LLC increased its holdings in Encompass Health by 39,783.3% in the 4th quarter. TFO Wealth Partners LLC now owns 2,393 shares of the company's stock valued at $160,000 after purchasing an additional 2,387 shares in the last quarter. The Treasurer of the State of North Carolina increased its holdings in shares of Encompass Health by 68.5% in the 4th quarter. The Treasurer of the State of North Carolina now owns 81,452 shares of the company's stock valued at $5,434,000 after purchasing an additional 33,113 shares in the last quarter. Allianz Asset Management GmbH increased its holdings in shares of Encompass Health by 701.7% in the 4th quarter. Allianz Asset Management GmbH now owns 192,350 shares of the company's stock valued at $12,834,000 after purchasing an additional 168,358 shares in the last quarter. TD Asset Management Inc increased its stake in Encompass Health by 239.6% in the 4th quarter. TD Asset Management Inc now owns 1,969,186 shares of the company's stock valued at $131,384,000 after purchasing an additional 1,389,275 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in Encompass Health by 192.3% in the 4th quarter. Parallel Advisors LLC now owns 573 shares of the company's stock valued at $38,000 after purchasing an additional 377 shares in the last quarter. 97.25% of the shares are owned by institutional investors.

Insider activity

In related news, CEO Mark J. Tarr sold 44,976 shares of the company's stock on Tuesday, April 30. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the CEO now owns 554,098 shares of the company's stock, valued at approximately $46,139,740.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Elissa Joy Charbonneau sold 10,000 shares of the company's stock on Friday, May 24. The shares were sold at an average price of $85.02, for a total transaction of $850,200.00. Following the completion of the sale, the insider now directly owns 18,594 shares of the company's stock, valued at $1,580,861.88. The sale was disclosed in a document filed with the SEC, which is accessible from the SEC website. Also, CEO Mark J. Tarr sold 44,976 shares of the company's stock in a transaction on Tuesday, April 30. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the completion of the sale, the CEO now owns 554,098 shares of the company's stock, valued at approximately $46,139,740.46. The disclosure regarding this sale can be found here. In the last three months, insiders have sold 69,519 shares of the company's stock, valued at $5,816,091. 2.10% of the shares are currently owned by insiders.

Analysts set new price targets

Several equities analysts have commented on the company. Truist Financial increased their price target on shares of Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Friday, February 9th. William Blair reiterated an “outperform” rating on shares of Encompass Health in a research report on Wednesday, February 7th. Raymond James reiterated a “strong-buy” rating and issued a $95.00 price target (up from $85.00) on shares of Encompass Health in a research report on Friday, April 26th. Mizuho increased their price target on shares of Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Finally, Barclays raised their price target on shares of Encompass Health from $101.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25. Eight investment analysts have rated the stock with a buy rating and one has assigned the company a strong buy rating. According to MarketBeat, Encompass Health has a consensus rating of “Buy” and an average price target of $92.00.

Read our latest stock analysis on EHC

Performance of Encompass Health shares

NYSE EHC rose $0.78 on Friday, reaching $86.39. The stock had a trading volume of 545,749 shares, compared to its average volume of 464,768. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.37. The company has a 50-day moving average of $83.02 and a 200-day moving average of $74.74. Encompass Health Co. has a 1-year low of $57.55 and a 1-year high of $87.94. The company has a market cap of $8.70 billion, a P/E ratio of 23.35, a price-to-earnings-growth ratio of 1.33 and a beta of 0.92.

Encompass Health (NYSE:EHC – Get Free Report) last released its quarterly earnings results on Wednesday, April 24. The company reported earnings per share of $1.12 for the quarter, beating analysts' consensus estimates of $0.93 by $0.19. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The company posted revenue of $1.32 billion for the quarter, compared to analyst expectations of $1.27 billion. During the same quarter last year, the company posted earnings per share of $0.88. Encompass Health's revenue grew 13.4% year-over-year. On average, equities analysts expect that Encompass Health Co. will post earnings per share of $4.1 for the current year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Monday, July 1st will receive a dividend of $0.15 per share. This represents an annualized dividend of $0.60 and a yield of 0.69%. The ex-dividend date of this dividend is Monday, July 1st. Encompass Health's dividend payout ratio is currently 16.22%.

About Encompass Health

(Free report)

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. The company owns and operates inpatient rehabilitation clinics that provide medical, nursing, therapeutic and ancillary services. The company provides specialized rehabilitation treatments on an inpatient basis to patients suffering from physical or cognitive disabilities or injuries due to conditions such as strokes, hip fractures and various debilitating neurological disorders.

Recommended Stories

This instant news alert was generated using narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial staff prior to publication. Please send questions or comments about this story to [email protected].

Before you consider Encompass Health, here's what you should hear.

MarketBeat tracks Wall Street's highest-rated and best-performing research analysts and the stocks they recommend to their clients every day. MarketBeat has identified the five stocks that top analysts are secretly whispering to their clients to buy now before the broader market catches on… and Encompass Health wasn't on the list.

While Encompass Health currently has a Buy rating from analysts, highly rated analysts believe these five stocks are better buys.

Check out the five stocks here

Click the link below and we'll send you MarketBeat's list of the seven best retirement stocks and explain why they belong in your portfolio.

Get this free report